Newsletter : 3fax1201.txt
| Previous file
| Next file
An E-Mail Letter to Help Israel:
"I came back from Israel two weeks ago after not having visited in seven years. I was
shocked by the poverty all around me - the closed shops and restaurants in downtown Tel
Aviv, the unemployment, the stories of hunger and hopelessness. Living in the Diaspora, we
all have the power to help. Every time you go to the supermarket, buy at least one Israeli
product... There are 200,000 Jews in Canada. If everyone bought an Israeli product every
two weeks, that would be around $200,000 making it to the desperate economy every few
weeks just from Canada. If the idea caught on with American Jews, that could be $5.2
million every couple of weeks. So, even if it you don't need it, if it is more expensive
than a Canadian or American product, if it looks less appetizing than its North American
counterpart, buy it and help Israel.
Unofficial Israeli-Palestinian Peace Plan to be Signed Monday
By Lisa Schlein (VOA-Geneva)
Hundreds of Israeli, Palestinian and international supporters of an unofficial Middle
East peace initiative known as the Geneva Accords, are expected to attend a signing
ceremony on Monday. Between 300 and 400 Israeli and Palestinian supporters of the Geneva
Accords were flying into Geneva on so-called peace flights. Former U.S. President Jimmy
Carter will be one of several distinguished guests scheduled to speak at the signing
ceremony. The Swiss government is paying much of the affair, including the flight for
reporters from Israel and the PA, for.
Former MK Yossi Beilin, the prime mover of the Geneva "agreement" formulated by several
left-wing MKs and others, says that the event will not be a signing - as the document was
already signed two months ago.
Syria has come out against the Geneva document, but a representative of the Saudi
Arabian kingdom will be on hand. Many PA organizations, such as the Al Aqsa Brigades, are
against the document, and shots were even fired over the weekend at the home of one of its
supporters, Yasser Abed Rabbo. Two key Palestinian Authority officials who were
instrumental in the formulation of the document - Kadoura Fares and Mohammed Horani - have
canceled their participation in the ceremony, the Saudi Press Agency reported, raising
still more doubts about the PA public's support for the document.
The Geneva Accords, which were negotiated in secret over the past two years, have
generated bitter debate. Prime Minister Ariel Sharon rejects the initiative as free-lance
diplomacy that is damaging to Israel. Palestinian leader Yasir Arafat welcomes it, as do
Secretary of State Colin Powell and United Nations Secretary-General Kofi Annan.
The Geneva Accords deal with so-called taboo issues. Like the internationally supported
"road map" to peace, this initiative envisages a two-state solution; but it goes further
in calling for the dismantling of most Israeli settlements, and it would split Jerusalem
into two capitals.
The Palestinian side agreed to waive the right of return to Israel by millions of
Palestinian refugees. In exchange, the Israeli side says it would grant sovereignty to the
Palestinians over a Jewish holy site, the Temple Mount.
A former United Nations High Commissioner for Human Rights, Mary Robinson, agreed that
the initiative would not succeed without official government backing. But she said public
opinion is important and can have a political momentum of its own.
Sharon Peace Initiative Faces Opposition from Israeli Army
By Ross Dunn (VOA-Jerusalem)
Israel's prime minister, Ariel Sharon, is reportedly in disagreement with top Israeli
army commanders over his plan to take unilateral action if peace talks with the
Palestinians break down. At the heart of the dispute is whether Israel should evacuate
Jewish settlements in the absence of a peace agreement.
Israeli media reported Sunday that Sharon's recent hints about the possible dismantling
of Jewish communities in the West Bank and Gaza Strip have not found favor with Israel's
top general. According to the reports, the head of the Israeli Defense Forces, General
Moshe Ya'alon, has expressed strong opposition in private to the proposals.
Ya'alon said he would support the evacuation of Jewish settlements only as part of a
comprehensive peace agreement with the Palestinians, according to Ha'aretz on Sunday. He
was reacting to Sharon's statements last week that, if the next round of peace
negotiations ends in failure, he would consider what he called unilateral steps to end the
conflict with the Palestinians.
Sharon said that Israel could not remain forever in all areas of the West Bank and Gaza
Strip. Israeli officials told reporters this could be taken to mean that Sharon is
weighing the possibility of evacuating some Jewish settlements and withdrawing troops from
parts of the territories.
The future of the Jewish settlements has become an emotive issue with Sharon's Cabinet.
At the Cabinet meeting on Sunday, the justice minister, Yosef Lapid, sharply criticized
Defense Minister Shaul Mofaz for what Lapid said was a lack of progress in dismantling new
Jewish outposts established without government approval.
Lapid said Israel is losing the battle for world support over the settlements issue,
and is even facing a rift with its main ally, the United States. Mofaz responded that the
Israeli army had removed at least 43 illegal Jewish outposts, and that more would be
dismantled in the near future.
Israeli Company Developing Alzheimer's Vaccine
By Israel Faxx News Services
An Israeli company has received a patent for the first vaccine against Alzheimer's
Israel21c.com reported that CEO of Mindset Bio-Pharmaceuticals, Daniel Chain, announced
his company's progress at the Society of Neuroscience Meeting in New Orleans. He pointed
out that preliminary studies carried out by the company indicate that Mindset's vaccine
may not cause the side effects that led Elan Corp. and Wyeth-Ayerst Laboratories to stop
an advanced stage clinical trial for their Alzheimer's vaccine in March 2002.
Alzheimer's disease continues to be a major incurable medical condition. It is a
degenerative neurological disorder that affects approximately 8 million people, with the
number rising dramatically with an increasing elderly world population.
Despite the disappointment of the vaccine being found to cause adverse side effects,
post-trial analysis of the data has shown that the vaccine was quite effective. "A recent
paper in a leading journal, Neuron, describes the lack of cognitive decline after one year
in 20 patients receiving the Elan vaccine," noted Cheryl Fitzer-Attas, Mindset`s Vice
President for Research & Development, as reported by Israel21c.com. "This underscores
the clinical promise for this type of treatment strategy."
"Mindset`s technology potentially addresses several major safety concerns for
developing a vaccine to beta-amyloid, a protein which is naturally present in the brain
and other tissues," said Chain. "These concerns include neurotoxicity of the native
protein and difficulties in inducing an antibody response in elderly patients."
With regard to another major safety concern - the potential of Alzheimer's vaccines to
induce an adverse autoimmune response - Mindset also offers good news. "In a related
discovery, we have found out how to anticipate and also reduce the possibility for this
undesirable reaction," said Fitzer-Attas.
The vaccine is still in the pre-clinical stage and is unlikely to enter clinical trials
before 2006, according to Chain.
"The vaccine will be first tried in healthy elderly volunteers in Phase I trials before
it can be tested in Alzheimer's patients (Phase II)," he said. "The Phase I trials would
be expected to take about a year to complete before Phase II can start. We can safely
assume at least seven or eight years before the vaccine could be approved by the FDA for
Given, the failure of a previous Alzheimer's vaccine trial that was sponsored by Wyeth
and Elan Pharmaceuticals and terminated prematurely because of safety issues, the
challenge will be to demonstrate safety. We believe Mindset's approach is potentially much
safer but it will be necessary to carry out extensive safety testing in animals and then
healthy humans before proceeding to patients."
(All material on these web pages is © 2001-2012
by Electronic World Communications, Inc.)